ACTOPLUS MET XR
Post-LOENDAORALTABLET, EXTENDED RELEASE
Approved
May 2009
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTOPLUS MET XR is a fixed-dose combination oral tablet containing pioglitazone and metformin in extended-release formulation, approved by the FDA in May 2009. The product is indicated for type 2 diabetes management as an adjunctive therapy. It combines insulin sensitizer (thiazolidinedione) and first-line antidiabetic (biguanide) mechanisms in a single extended-release dosage form.
Post-LOEPost-LOE
Product is in post-loss-of-exclusivity phase with moderate competitive pressure (35/100), indicating a mature brand team focused on market maintenance and generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on ACTOPLUS MET XR at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.